SIGY · Sigyn Therapeutics, Inc. · Executive Compensation
$0.03
0.00 (-6.27%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“The Company had an accumulated deficit of $17,379,978 at September 30, 2025, had a working capital deficit of $3,903,920 at September 30, 2025, had net losses of $578,503 and $2,698,254, and $1,196,923 and $2,817,394 for the three and nine months ended September 30, 2025 and 2024, respectively, and net cash used in operating activities of $646,208 and $582,218 for the nine months ended September 30, 2025 and 2024, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Market Cap
$56,188
Shares
1.61M
Volume · Oct 2
27.05K
Avg daily vol (3M)
30.56K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Ryan | Board of Directors | Resigned | 2025-08-15 |
| Christopher Wetzel | Board of Directors | Resigned | 2025-08-15 |
| Richa Nand | Board of Directors | Resigned | 2025-08-15 |
| Gerald DeCiccio | Chief Financial Officer | Retired | 2025-03-07 |
| Michael Ryan | Board of Directors | Appointed | 2025-01-16 |
| Jerry DeCiccio | Chief Financial Officer | Appointed | 2023-12-12 |
| Jeremy Ferrell | CFO | Terminated | 2023-12-12 |
| Christopher Wetzel | Director | Appointed | 2022-10-05 |
| Richa Nand | Director | Appointed | 2022-10-05 |
| Jim Dorst | Director | Appointed | 2022-10-05 |